

ILARIS (canakinumab) (non-preferred) PRIOR AUTHORIZATION FORM

Cytokine and CAM Antagonists and Quantity Limits/Daily Dose Limits prior authorization guidelines are accessible on the Department's Pharmacy Services website at <http://www.dhs.pa.gov/provider/pharmacyservices/index.htm>.

| PRIOR AUTHORIZATION REQUEST INFORMATION | | PRESCRIBER INFORMATION | |
|---|--|-------------------------|------------------|
| <input type="checkbox"/> New request | <input type="checkbox"/> Renewal request | Total # of pages: _____ | Prescriber name: |
| Name of office contact: | | Specialty: | |
| Contact's phone number: | | State license #: | |
| LTC facility contact/phone: | | NPI: | MA Provider ID#: |
| RECIPIENT INFORMATION | | Street address: | |
| Recipient Name: | | Suite #: | City/state/zip: |
| Recipient ID#: | DOB: | Phone: | Fax: |

CLINICAL INFORMATION

| | | | |
|---|--|---------------------|----------|
| Medication requested: | <input type="checkbox"/> Ilaris 150 mg/ml subcutaneous injection vial <input type="checkbox"/> Ilaris 180 mg subcutaneous injection vial <input type="checkbox"/> Ilaris _____ | # of vials: | Refills: |
| Dose: _____ mg | Frequency: <input type="checkbox"/> every 4 weeks <input type="checkbox"/> every 8 weeks <input type="checkbox"/> other (specify): _____ | | |
| Recipient weight: _____ lbs/kg | Diagnosis: | DX code (required): | |
| Specialty Pharmacy Drug Program: | Ilaris is part of the DHS Specialty Pharmacy Drug Program and is only available from one of the two DHS specialty pharmacies – Walgreen's Specialty Pharmacy . | | |

INITIAL request – complete questions applicable to recipient's diagnosis

| | |
|--|---|
| 1. Check all that apply to the recipient and <u>submit documentation for each</u> . | |
| <input type="checkbox"/> vaccinated for hepatitis B | <input type="checkbox"/> up-to-date with all age-appropriate immunizations |
| <input type="checkbox"/> screened for hepatitis B (surface antigen & core antibody) | <input type="checkbox"/> screened for tuberculosis |
| 2. Does the recipient have one of the following diagnoses? (<i>Check applicable diagnosis.</i>) | |
| <input type="checkbox"/> periodic fever syndrome | <input type="checkbox"/> Yes <i>Submit all supporting documentation of differential diagnosis.</i> |
| <input type="checkbox"/> cryopyrin-associated periodic syndrome (CAPS) | |
| <input type="checkbox"/> familial cold autoinflammatory syndrome (FCAS) | <input type="checkbox"/> No <i>Submit documentation supporting the use of Ilaris for the recipient's diagnosis.</i> |
| <input type="checkbox"/> Muckle-Wells syndrome (MWS) | |
| <input type="checkbox"/> familial Mediterranean fever (FMF) | |
| <input type="checkbox"/> hyperimmunoglobulin D syndrome/mevalonate kinase deficiency (HIDS/MKD) | |
| <input type="checkbox"/> TNF receptor-1 associated periodic syndrome (TRAPS) | |
| <input type="checkbox"/> systemic juvenile idiopathic arthritis (sJIA) | |
| 3. <u>For a diagnosis other than the approved indication(s)</u> , submit documentation supporting the use of the requested medication for the recipient's diagnosis & other treatments tried. | |

RENEWAL request

| | |
|---|--|
| 1. While on Ilaris, did the recipient experience improvement in disease activity and/or level of functioning? | <input type="checkbox"/> Yes <i>Submit documentation of recipient's response to therapy.</i> |
| | <input type="checkbox"/> No |

PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO DHS – PHARMACY DIVISION

| | |
|------------------------------|--------------|
| Prescriber Signature: | Date: |
|------------------------------|--------------|

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.